Home > Rheumatology > WPPAC 2021 > Disease Progression > Active PsA: Biomarkers distinguish radiographic progressors from non-progressors

Active PsA: Biomarkers distinguish radiographic progressors from non-progressors

Conference
WPPAC 2021
Trial
Phase 3, SPIRIT-P1
Patients with psoriatic arthritis (PsA) who progress to radiographic damage can potentially be discriminated from those who do not progress by 103 biomarker peptides, corresponding to 69 proteins. This has been identified using 2 complementary proteomic approaches and a combination of univariate and machine learning statistical analysis [1]. A delay in the diagnosis and treatment of patients with PsA leads to poor radiographic and functional outcomes [2]. So, identifying which patients might progress radiographically is essential. This unmet need has been recognised by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) [3]. Biomarkers for radiographic joint damage could assist in early-stage identification of patients likely to progress as well as identifying those who are progressing despite therapy. The previous phase 3 SPIRIT-P1 trial (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on